Compare Davita Inc (DVA) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Jones Lang LaSalle Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Jones Lang LaSalle Inc trades at $362.41 (market cap $16.44B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | JLL | |
|---|---|---|
Market Cap | $11.72B | $16.44B |
Sector | Health | Real Estate |
52-Week High | $240.96 | $373.24 |
52-Week Low | $103.87 | $280.16 |
Enterprise Value | $24.44B | $19.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
JLL trades at $362.38, down 0.36% on the day, near its 52-week high. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M, and analysts project further growth in 2026. Positive sentiment is driven by strong Q2 2026 results and AI-related real estate demand highlighted in recent company research.
Outlook remains positive with a consensus price target of $391.50, though risks include market volatility and execution challenges in capital markets. The stock offers growth potential from expanding profit margins and strategic positioning in AI-impacted real estate sectors, balanced by economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
